The metabolic syndrome and cardiovascular disease

Annals of Medicine

Volumn 38, Issue 1, 2006, Pages 64-80

  Bonora, Enzo ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Cardiovascular disease; Central obesity; Dyslipidaemia; Hypertension; Insulin resistance; Metabolic syndrome; Microalbuminuria; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; URATE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPARATIVE STUDY; DIABETES MELLITUS; FIBRINOLYSIS; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOPHILIA; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION;

EID: 31744432315     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890500401234     Document Type: Review

References (211)

1. Kylin E. Studien uieber das Hypertonie-Hyperglykamie- Hyperurikamiesyndrom. Zentralblatt fuer Innere Medizin. 1923;44:105-27.
2. Vague J. La differenciation sexuelle, factor determinants des formes de l'obesite. Press Med. 1947;30:339-40.
3. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat. 1967;4:572-90.
4. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
5. IDF Consensus. The IDF Consensus worldwide definition of the Metabolic Syndrome. http://www.idf.org./home/ index.cfm?node=1388
6. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization, Geneva, Switzerland, 1999. Publication WHO/NCD/NCS/99.2.
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
8. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.
9. Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med. 1989;149:1514-20.
10. Modan M, Halkin H, Almong S, Lusky A, Eshkol A, Shefi M, et al. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809-17.
11. Hjiermann I. The Metabolic Cardiovascular Syndrome: Syndrome X, Reaven's Syndrome, Insulin Resistance Syndrome, and Atherothrombotic Syndrome. J Cardiovasc Pharmacol. 1992;20(suppl 8):S5-10.
12. Zimmet PZ. Hyperinsulinemia. How innocent a bystander? Diabetes Care. 1993;16(suppl 3):56-70.
13. Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M. Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia. 2000;43:156-64.
14. Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, et al. Distinct risk profiles of early and advanced atherosclerosis. Prospective results from the Bruneck Study. Arterioscl Thromb Vasc Biol. 2000;20:529-37.
15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035-8.
16. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44.
17. Manson JE, Colditz GA, Stampfer MJ, Willet WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-7.
18. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389-401.
19. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and the level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21:1167-72.
20. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savage PJ. Diabetes mellitus, subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arterioscl Thromb Vasc Biol. 2000;20:823-9.
21. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, et al. for the FINMONICA Myocardial Infarction Register Study Group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
22. Olsson T, Viitanen M, Asplund K, Eriksson S, Hagg E. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia. 1990;33:244-9.
23. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population,. 1971-1993. Diabetes Care. 1998;21: 1138-45.
24. De Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. Diabetes Care. 1999;22:756-61.
25. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med. 2001;161:397-404.
26. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15-8.
27. United Kingdom Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
28. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care. 2003;26:3160-7.
29. Kannel WB, LeBauer EJ, Dawber TR, McNamara PM. Relation of body weight to development of coronary heart disease: The Framingham Study. Circulation. 1967;35: 734-44.
30. Harris TB, Ballard-Barbash R, Madans J, Makuc DM, Feldman JJ. Overweight, weight loss, and risk of coronary heart disease in older women: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1993;12: 1318-27.
31. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH. Diabetes incidence in Pima Indians: contribution of obesity and parental diabetes. Am J Epidemiol. 1981;113: 144-51.
32. Garrison RJ, Wilson PWF, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism. 1980;29:1053-60.
33. Stamler R, Stamler J, Reidlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 milion Americans. JAMA. 1978;240:1607-10.
34. Huber HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-77.
35. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Momson RR, et al. A prospective study of obesity and risk of coronary hearth disease in women. N Engl J Med. 1990;322:882-9.
36. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in. 1913. BMJ. 1984;288:1401-4.
37. Lapidus L, Bengsston C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow up of participants in the population study of women in Gotheburg, Sweden. BMJ. 1984;289:1257-61.
38. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the Study of Men Born in. 1913. Diabetes. 1985;34:1055-8.
39. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132-43.
40. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease. A statement for the Healthcare professionals from the American Heart Association. Circulation. 1999;100: 1134-46.
41. Bonora E, Zenere M, Branzi P, Bagnani M, Maggiulli L, Tosi F, et al. Influence of body fat and its regional localization on risk factors for atherosclerosis in young men. Am J Epidemiol. 1992;135:1271-8.
42. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-8.
43. Bonora E, Del Prato S, Bonadonna R, Gulli G, Solini A, Shank M, et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes. 1992;41:1151-9.
44. Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes. 2000;24(suppl. 2):S32-5.
45. Seidell JC, Oosterlee A, Thijssen MAO, Burema J, Deurenberg P, Hautvast JGAJ, et al. Assessment of intra-abdominal and subcutaneous abdominal fat: Relation between anthropometry and computed tomography. Am J Clin Nutr. 1987;45:7-13.
46. Bonora E, Micciolo R, Ghiatas AA, Lancaster JL, Alyassin A, Muggeo M, et al. Is it possible to derive a reliable estimate of human visceral and subcutaneous abdominal tissue from simple anthropometric measurements? Metabolism. 1995;44:1617-25.
47. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23:465-71.
48. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti D, Newell-Morris L, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men. Diabetes Care. 1999; 1808-12.
49. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9.
50. Gotto AM Jr. Triglyceride: the forgotten risk factor. Circulation. 1998;97:1027-8.
51. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol. 1998;31:1252-7.
52. Tanne D, Koren-Morag N, Graff E, Goldbourt U. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation. 2001;104:2892-7.
53. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992;70:733-7.
54. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115(Suppl 8A):24S-8.
55. Halle M, Berg A, Baumstark MW, Konig D, Huonker M, Keul J. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels. Atherosclerosis. 1999;143: 185-92.
56. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med. 1999;340:115-26.
57. Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 1995;15:1819-28.
58. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-8.
59. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
60. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-81.
61. Bonora E, Targher G, Branzi P, Zenere M, Saggiani F, Zenti MG, et al. Cardiovascular risk profile in 38-yr and 18-yr-old men. Contribution of body fat content and regional fat distribution. Int J Obes. 1996;20:28-36.
62. Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, et al. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care. 1998;21:221-30.
63. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-32.
64. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, et al. The double jeopardy of HDL. Ann Med. 2005;37:173-8.
65. Kannel WB, Gordon T, Schwartz MJ. Systolic vs. diastolic blood pressure and risk of coronary artery disease. The Framingham Study. Am J Med. 1971;27:335-46.
66. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504-14.
67. O'Donnell CJ, Kannel WB. Cardiovascular risks of hypertension: lessons from observational studies. J Hypertens. 1998;16(suppl 1):S3-7.
68. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J. 1999;138(3 Pt 2):211-9.
69. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet. 2004;364:937-52.
70. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-7.
71. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-52.
72. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N Engl J Med. 1900;323:22-7.
73. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-46.
74. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-8.
75. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation. 2003;107:2805-9.
76. Viberti G. Etiology and prognostic significance of albuminuria in diabetes. Diabetes Care. 1988;11:840-5.
77. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157-65.
78. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093-100.
79. Borch-Johnsen K, Feldt-Rasmussen, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999;19:1992-7.
80. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-5.
81. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, et al. Characterization of cellular defects of insulin action in type II (non-insulin-dependent) diabetes mellitus. J Clin Invest. 1993;91:484-94.
82. Bonora E, Bonadonna RC, Del Prato S, Gulli G, Solini A, Matsuda M, et al. In vivo glucose metabolism in obese and type II diabetic subjects with and without hypertension. Diabetes. 1993;42:764-72.
83. Bonora E, Targher G, Alberiche M, Formentini G, Calcaterra F, Marini F, et al. Predictors of insulin sensitivity in type 2 diabetes mellitus. Diabetic Med. 2002;19:535-42.
84. Bonora E, Targher G, Alberiche M, Bonadonna RC, Zenere MB, Saggiani F, et al. Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2001;86:2073-9.
85. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:703-6.
86. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes. 1998;47:1643-9.
87. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyorala K, Salonen JT, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991;11:1068-76.
88. Inchiostro S, Bertoli G, Zanette G, Donadon V. Evidence of higher insulin resistance in NIDDM patients with ischaemic heart disease. Diabetologia. 1994;37:597-603.
89. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary heart disease. Diabetologia. 1996;39:1345-50.
90. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. and the Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809-17.
91. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R, et al. Intimal-medial thickness of the carotid artery in nondiabetic and non-insulin-dependent diabetic subjects. Relationship with insulin resistance. Diabetes Care. 1997;20:627-31.
92. Hanley AJG, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25:1177-84.
93. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002;19:470-5.
94. Robins SJ, Bloomfield Rubins H, Faas FH, Schaefer EJ, Elam MB, et al. on behalf of the VA-HIT Study Group. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veteran Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26:1513-7.
95. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degree of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
96. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is a independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25:1135-41.
97. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R, et al. The Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes. 2003;27:1283-9.
98. Toft I, Bonaa KA, Ingebretsen OC, Nordoy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol. 1997;17: 553-9.
99. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care. 1998;21:649-54.
100. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Insulin resistance, hemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetic men with and without coronary heart disease. Diabetologia. 2004;47:1557-65.
101. Yudkin JS, Stehouwer JJ, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8.
102. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Aimeras N, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102:179-84.
103. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, et al. The Metabolic Syndrome, circulating oxidized LDL, and risk of myocardial infarction in a well functioning elderly people in the Health, Aging and Body Compostion Cohort. Diabetes. 2004;53:1068-73.
104. Byrne CD, Maison P, Halsall D, Martensz N, Hales CN, Wareham NJ. Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the Metabolic Syndrome. Diabet Med. 1999;16:1007-15.
105. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharret AR, et al. for the Atherosclerosis Risk in Community Study Investigators. Clustering of dyslipidemia, hypeuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in the general population. Metabolism. 1996;45:699-706.
106. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7.
107. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-5.
108. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-92.
109. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998;21:62-8.
110. Hak AE, Pols HA, Stehouwer CD, Mejer J, Kiliaan AJ, Hofman A, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. J Clin Endocrinol Metab. 2001;86:4398-405.
111. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, et al. Fasting plasma homocystein levels in the Insulin Resistance Syndrome. Diabetes Care. 2001;24:1403-10.
112. Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, Walton C, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998;18:928-33.
113. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 2004;35:2248-52.
114. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and the Metabolic Syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
115. Nagi DK, Tracy R, Pratley R. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism. 1996;45:1243-7.
116. Festa A, D'Agostino R jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:562-8.
117. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994;78:25-9.
118. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism. 2002;51:743-9.
119. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulienemia. J Clin Endocrinol Metab. 2001;86: 1930-5.
120. Donahue RP, Prineas RJ, Donahue RD, Zimmet P, Bean JA, De Courten M, et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. Diabetes Care. 1999;22:1092-6.
121. Falk E, Shah PK, Fuster V. Pathogenesis of plaque dysruption. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Vol. 2. Philadelphia: Lippincott-Raven, 1996. p. 492-510.
122. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-5.
123. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascolar disease. The Framingham Study. JAMA. 1987;258:1183-6.
124. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
125. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-7.
126. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792-801.
127. Anand S, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Davis B, et al., for the Study of Health Assessment and Risk in Ethnic Groups (SHARE) and Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP) Investigators. Relation of the Metabolic Syndrome and Fibrinolytic Disfunction to Cardiovascular Disease. Circulation. 2003;108:420-5.
128. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 2001;86:366-73.
129. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Metha JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(suppl IV):6-19.
130. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 1984;4:79-83.
131. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J. 2004;148:596-601.
132. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273-8.
133. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-478.
134. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-21.
135. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20: 2243-7.
136. Bonadonna R, Bonora E. Glucose and free fatty acid metabolism in human obesity. Relationship with insulin resistance. Diabetes Rev. 1997;5:21-51.
137. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia. 2002;45:623-34.
138. Jouven X, Charles MA, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as predictive risk factor for sudden death in the population. Circulation. 2001;104:756-61.
139. Saggiani F, Pilati S, Targher G, Branzi P, Muggeo M, Bonora E. Serum uric acid and related factors in 500 hospitalized subjects. Metabolism. 1996;45:1557-61.
140. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Intern Med. 1999;131:7-13.
141. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283:2404-10.
142. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-51.
143. Schlotte V, Sevanian A, Hochstein P, Weithmann KU. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro. Free Radic Biol Med. 1998;25:839-47.
144. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42.
145. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.
146. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
147. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27:889-94.
148. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-43.
149. Ridker PM, Buring J, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
150. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
151. Brown DW, Giles WH, Croft JB. White blood cell counts an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol. 2001;54: 316-22.
152. Erikssen G, Liestol K, Bjornholt JV, Stormorken H, Thaulow E, Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J. 2000;21:1614-20.
153. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck Study. Circulation. 1997;96:3300-7.
154. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, et al. Chronic infections and the risk of carotid atherosclerosis. Prospective results from a large population study. Circulation. 2001;103:1064-70.
155. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-92.
156. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-53.
157. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future mycardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
158. Cinnes DB, Pollak ES, Buck CA, Loscalzo J, Zimmermann GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-61.
159. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14:506-12.
160. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The atherosclerosis risk in communities (ARIC) study. Circulation. 1997;96:4219-25.
161. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecole-1 and risk of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
162. Ridker PM, During JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491-5.
163. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-5.
164. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 1999;11:327-32.
165. Chandran M, Phillips SA, Ciaraldi T, Henry RP. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442-50.
166. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96:939-49.
167. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1634-42.
168. Shin HJ, Oh J, Kang SM, Lee JH, Shin MJ, Hwang KC, et al. Leptin induces hypertrophy via p38 mitogen-activated protein kinase in rat vascular smooth muscle cells. Biochem Biophys Res Commun. 2005;329:18-24.
169. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291:1730-7.
170. Wallace AM, McMahon AD, Packard CJ, Kelly A, Sheperd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104: 3052-6.
171. Ford ES, Giles W, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-9.
172. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and al alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002;28:364-76.
173. Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52:2160-7.
174. Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, Fortmann SP, Haffner SM, et al. Predictors of the incident Metabolic Syndrome in adults. The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:788-93.
175. Modkad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of obesity epidemic in the United States. 1991-1998. JAMA. 1999;282:1519-22.
176. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
177. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
178. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-94.
179. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes care. 2001;24:683-9.
180. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
181. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R, et al. Carotid atheroclerosis and coronary heart disease in the Metabolic Syndrome. Prospective data from the Bruneck Study. Diabetes Care. 2003;26:1251-7.
182. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DStJ, Haffher SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003;108:414-9.
183. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-7.
184. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21:52-8.
185. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic european men and women. Arch Intern Med. 2004;164:1066-76.
186. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-7.
187. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110: 1245-50.
188. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136-41.
189. McNeill A, Rosamond WD, Girman CJ, Hill Golden S, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2005;28:385-90.
190. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PWF. C-reactive protein, the Metabolic Syndrome and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-5.
191. Scuteri A, Najjar SS, Morrell CH, Lakatta EG. Cardiovascular Health Study. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care. 2005;28:882-7.
192. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112:666-73.
193. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.
194. Einhorn D, Reaven GM, Cobin RH. American College of Endocrinology position statement on the Insulin Resistance Syndrome. Endocr Pract. 2002;9:236-52.
195. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123-8.
196. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men. The 22 follow-up results of the Helsinki Policemen Study. Arterioscl Thromb Vasc Biol. 2000;20:538-44.
197. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001;24: 1629-33.
198. Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289-304.
199. O'Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigens after temporary reversion to traditional lifestyle. Diabetes. 1984;33: 596-603.
200. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, et al. Reduction of inflammatory cytokine concentration and improvement of endothelial functions in obese women after weight loss for one year. Circulation. 2002;105:804-9.
201. Kopp HP, Kopp CW, Festa A, Kryzanowska K, Kriwanek S, Minar E, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042-7.
202. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol. 2001;87:827-31.
203. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991;229:181-7.
204. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29(4 Pt 2):6S44-52.
205. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16:621-9.
206. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-74.
207. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-84.
208. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26:172-8.
209. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413-23.
210. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26:2493-9.
211. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.